Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 11:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,784 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: MAJOR DEPRESSIVE DISORDER Clear all
Completed No phase listed Observational Results available

Treatment-Resistant Depression Registry

NCT00320372
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Cyberonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
55
States / cities
Tucson, Arizona • Beverly Hills, California • Garden Grove, California + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Oct 5, 2026, 11:05 AM EDT
Completed Phase 3 Interventional

A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode

NCT00094432
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
40
States / cities
Mesa, Arizona • La Mesa, California • La Palma, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 5, 2026, 11:05 AM EDT
Completed Phase 2 Interventional

Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder

NCT05399498
View directory record Official record
Conditions
Borderline Personality Disorder, Major Depressive Disorder
Interventions
Psilocybin
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 5, 2026, 11:05 AM EDT
Completed Not applicable Interventional Results available

Cognitive Fitness for Depression in Older Adults

NCT04790630
View directory record Official record
Conditions
Depression Mild, Depressive Disorder, Major, Mild Cognitive Impairment
Interventions
Computerized Cognitive Remediation of Executive Functioning (CCR-EF), Active Control
Other
Lead sponsor
UConn Health
Other
Eligibility
60 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 5, 2026, 11:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Serum Markers as a Bioassay for Unipolar Depression

NCT00825799
View directory record Official record
Conditions
Major Depression
Interventions
Not listed
Lead sponsor
Steward St. Elizabeth's Medical Center of Boston, Inc.
Other
Eligibility
18 Years to 60 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 3, 2014 · Synced Oct 5, 2026, 11:05 AM EDT
Recruiting Phase 4 Interventional

Aβ Dynamics in LLMD

NCT05004987
View directory record Official record
Conditions
Alzheimer Disease, Major Depressive Disorder
Interventions
Escitalopram Oxalate, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
New York, New York • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 5, 2026, 11:05 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Depression, Epinephrine, and Platelet Function

NCT00166114
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Desipramine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 23, 2015 · Synced Oct 5, 2026, 11:05 AM EDT
Completed Phase 2 Interventional

Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients

NCT06836063
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Ropanicant, Placebo
Drug
Lead sponsor
Suven Life Sciences Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
35
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 5, 2026, 11:05 AM EDT
Recruiting Not applicable Interventional

Accelerated Intermittent Theta Burst in Treatment-Naive Adolescents

NCT06523439
View directory record Official record
Conditions
Major Depressive Disorder, Depression in Adolescence, Depression, Major Depressive Episode
Interventions
MagPro X100 edition (MagVenture, Skovlunde, Denmark)
Device
Lead sponsor
University of Texas at Austin
Other
Eligibility
13 Years to 20 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 5, 2026, 11:05 AM EDT
Completed Phase 2 Interventional Results available

Double-Blind Treatment of Major Depressive Disorder With Vilazodone

NCT01742832
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vilazodone, Citalopram
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 60 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 5, 2026, 11:05 AM EDT
Not yet recruiting No phase listed Observational

Using Integrated Care and Wearable Technology to Evaluate Outcomes of the Shields & Stripes Program for Veterans and First Responders

NCT07452900
View directory record Official record
Conditions
Holistic Care, Mental Health, Sleep, PTSD, Depression - Major Depressive Disorder, Anxiety, Resilience, Recovery, Occupation, Biometrics Measurement, Veteran, Quality of Life
Interventions
Not listed
Lead sponsor
Baylor University
Other
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Waco, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 5, 2026, 11:05 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (SIRIUS)

NCT00385307
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
amibegron (SR58611A)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Oct 5, 2026, 11:05 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Kappa Opioid Receptor Imaging in Depression (KOR Depression)

NCT02236702
View directory record Official record
Conditions
Major Depressive Disorder, Anhedonia
Interventions
Positron Emission Tomography (PET) imaging
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2016 · Synced Oct 5, 2026, 11:05 AM EDT
Completed Phase 4 Interventional

Pharmacotherapy in Depression With Panic Spectrum

NCT00177996
View directory record Official record
Conditions
Major Depression
Interventions
sertraline hydrochloride
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2016 · Synced Oct 5, 2026, 11:05 AM EDT
Terminated Phase 4 Interventional Results available

Predicting SSRI Efficacy in Veterans With PTSD

NCT04183205
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Major Depressive Disorder
Interventions
LDAEP, Placebo, sertraline
Diagnostic Test · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 5, 2026, 11:05 AM EDT
Terminated Not applicable Interventional Results available

Efficacy and Safety Study of NeuroStar TMS Therapy in Patients With Major Depressive Disorder With Postpartum Onset

NCT01842542
View directory record Official record
Conditions
Depression, Postpartum
Interventions
NeuroStar Transcranial Magnetic Stimulation (TMS)
Device
Lead sponsor
Neuronetics
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
8
States / cities
Hartford, Connecticut • Gainesville, Florida • Pensacola, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 5, 2026, 11:05 AM EDT
Completed No phase listed Observational

Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Sleep Deprivation

NCT05893173
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Sleep Deprivation
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 5, 2026, 11:05 AM EDT
Terminated Phase 2 Interventional Results available

Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)

NCT04634669
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Disorder
Interventions
AXS-05 (dextromethorphan-bupropion)
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
20
States / cities
Little Rock, Arkansas • Redlands, California • Sherman Oaks, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 5, 2026, 11:05 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

NCT03738215
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
65
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 5, 2026, 11:05 AM EDT
Completed Phase 2 Interventional Results available

Electroacupuncture for Major Depression

NCT00071110
View directory record Official record
Conditions
Depression, Depressive Disorder
Interventions
Electroacupuncture, Sham
Procedure
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 80 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2010 · Synced Oct 5, 2026, 11:05 AM EDT
Completed Phase 2 Interventional Results available

A Study of CX157 (TriRima) for the Treatment of Depression

NCT00739908
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
CX157 (TriRima), Placebo
Drug
Lead sponsor
CeNeRx BioPharma Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
14
States / cities
Birmingham, Alabama • Beverly Hills, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2012 · Synced Oct 5, 2026, 11:05 AM EDT
Recruiting Phase 3 Interventional

Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

NCT07484217
View directory record Official record
Conditions
Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Interventions
Solriamfetol 150 MG, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
40
States / cities
Tucson, Arizona • Bellflower, California • Chino, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 5, 2026, 11:05 AM EDT
Completed Not applicable Interventional

Cognitive Behavioral Treatment for Post-Traumatic Stress Disorder in People With Additional Serious Mental Illnesses

NCT00494650
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Cognitive behavioral therapy (CBT), Brief PTSD treatment
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
5
States / cities
Monmouth Junction, New Jersey • New Brunswick, New Jersey • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 8, 2012 · Synced Oct 5, 2026, 11:05 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

PET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine.

NCT07095205
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Nicotine transdermal patch, PET Scan with [18F] VAT
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 5, 2026, 11:05 AM EDT